AB Science receives several European countries approval to initiate the confirmatory phase 3 study of masitinib in ALS
AB Science SA, is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announced that the confirmatory phase 3 study with masitinib in amyotrophic lateral sclerosis (ALS), study AB23005, has …